Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 500 shares of the company's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $23.47, for a total value of $11,735.00. Following the completion of the transaction, the director directly owned 77,531 shares in the company, valued at approximately $1,819,652.57. The trade was a 0.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amphastar Pharmaceuticals Stock Performance

Amphastar Pharmaceuticals stock traded down $0.41 during trading hours on Friday, reaching $23.18. 221,782 shares of the company were exchanged, compared to its average volume of 494,740. Amphastar Pharmaceuticals, Inc. has a 12 month low of $22.64 and a 12 month high of $53.96. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80. The stock has a 50-day moving average of $24.75 and a 200 day moving average of $29.05. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 8.40, a PEG ratio of 6.14 and a beta of 0.72.

Wall Street Analyst Weigh In

AMPH has been the subject of several recent research reports. Wells Fargo & Company decreased their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $32.33.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Smartleaf Asset Management LLC raised its holdings in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after acquiring an additional 493 shares during the period. Signaturefd LLC grew its position in shares of Amphastar Pharmaceuticals by 147.7% in the first quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after purchasing an additional 520 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $38,000. Tower Research Capital LLC TRC increased its position in Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares during the period. Finally, IFP Advisors Inc acquired a new position in Amphastar Pharmaceuticals during the 1st quarter valued at $34,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.